Figure 3 | Scientific Reports

Figure 3

From: Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Figure 3

Prostate Cancer Biomarker Panel Differentiates Lower Urinary Tract Symptoms/Benign Prostate Hyperplasia (LUTS/BPH) from Prostate Cancer (PCa) in Patients who have had multiple biopsies. (A) Beeswarm and boxplot graphs showing median, interquartile range and distribution of age (years), prostate volume (mL), serum FLNA concentrations (pg/mL), and serum PSA concentrations (ng/mL) from patients who have had multiple biopsies. Data represents n = 94 LUTS/BPH and n = 477 PCa. (B) Receiver operator characteristics (ROC) curve for prostate cancer biomarker panel demonstrates better performance in differentiating patients with LUTS/BPH from PCa compared to PSA alone. Area under the curve (AUC) for the panel is 0.87 versus PSA alone 0.57. Shaded grey regions indicate standard error.

Back to article page